The ITHANET virtual information day will be held virtually on September 29th 14:00 – 17:00 GMT+3.
ITHANET: updates and collaborations on haemoglobinopathies
read more...
haemoglobinopathies
TIF releases updated guidelines for transfusion-dependent thalassaemia
TIF has just published the updated Version 2.0 of the Guidelines for The Management of Transfusion-Dependent Thalassaemia (TDT) – 4th Edition
Rare disease research: innovative methodologies and digitalisation
The event “Metodologie innovative e digitalizzazione per la ricerca sulle malattie rare: esperienza e risultati nelle emoglobinopatie” will be held on 18 July 2022 at 8.30AM CEST in Bari (Italy), at the Regional Council of Apulia headquarters.
INHERENT Network Presented at ASH Annual Meeting
The 63rd ASH Annual Meeting was held as a hybrid meeting at the Georgia World Congress Center in Atlanta from December 11-14, 2021.
EMA Recommends Oxbryta® for Sickle Cell Anaemia
The Committee for Medicinal Products for Human Use at the EMA adopted a positive opinion recommending marketing authorization for Oxbryta® (voxelotor) for the treatment of haemolytic anaemia due to sickle cell disease in patients 12 years of age and older
INHERENT: advancing genetic research on Haemoglobinopathies
We are excited to announce a paper about the recently formed International Hemologlobinopathy Research Network – INHERENT, published in the American Journal of Hematology.
TIF Guidelines for transfusion-dependent thalassaemia: 4th edition
Thalassaemia International Federation has published the 4th Edition of the TIF Guidelines for The Management of Transfusion-Dependent Thalassaemia.
Blood donations: a lifeline for thalassemia patients during covid19
A new initiative on blood transfusions and on the value of the blood donations was launched.
COVID-19 risk for thalassaemia and sickle cell disease patients
COVID-19 pandemic impacts the whole society in terms of socio-economic challenges as well as on the healthcare system worldwide. COVID-19 has been proven to be life-threatening to all patients especially those suffering from serious diseases.
EMA recommends Crizanlizumab for Sickle Cell Disease in adults
The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) gave a positive opinion, recommending the granting of a conditional marketing authorisation for Crizanlizumab (Adakveo®) in patients with Sickle Cell Disease from 16 years of age.
Recent posts in Haemoglobinopathies